German construction sector still in recession, civil engineering only bright spot
LONDON - Provexis plc (AIM:PXS), developer of the Fruitflow heart-health food ingredient, announced Tuesday it will miss the September 30 deadline for publishing its audited financial statements for the year ended March 31, 2025, triggering a temporary suspension from trading on AIM.
The company expects the audit to be completed by mid-October 2025, with trading suspension taking effect Wednesday morning. Provexis attributed the delay to ongoing work with its new auditors, RPG Crouch Chapman LLP, in their first year as the group’s auditor.
In an unaudited trading update, Provexis reported expected sales of £1.29 million for the year ended March 31, representing a 61% year-on-year increase. The company anticipates an underlying operating loss of £278,000, an improvement from the £469,000 loss reported in the previous year.
The company disclosed cash reserves of £708,000 as of March 31, with net assets exceeding £750,000.
For the six months ended September 30, Provexis reported it has sold all remaining Fruitflow II SD inventory previously purchased from dsm-firmenich. A new production run has been completed, with delivery expected in October 2025, two months later than planned due partly to personnel changes at a supply chain partner.
The company expects sales for the six months ended September 30 to exceed £350,000, with additional sales anticipated in the quarter ending December 31, 2025.
Provexis plans to hold its Annual General Meeting on November 21, 2025, at the offices of Allenby Capital Limited in London.
The information was disclosed in a regulatory news service announcement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.